News Formal

A ranch that belongs to one of the founding families of Aspen just hit the market for $18 million — here's an inside look at the sprawling property

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 51%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

Built in 2002, the $18 million ranch sits on 12 acres of mountainside property, just a 10-minute drive from the center of Aspen. Take a look inside.

While the main house was built in 2002, the Paepcke family has owned the land for 70 years. According to, the family began dividing the original 400 acres purchased by Walter Paepcke following his death in 1960.

Today, four lots remain — each around 12 acres — surrounding a 51-acre common area. The largest, his daughter's property, contains the Erickson Ranch mansion. Two of the other lots also feature residences built in the early 2000s, while the last one remains empty and is under construction for new development.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex... I'll remember this. Why don’t they learn how to use CBDa? I take issue with the quote attributed to Guggenheim analyst, Yaris Suneja. You would not consider investment in Alzheimer ‘s research a “waste” if a loved one were so afflicted. This is a devastating disease. It takes a brave company to find an answer.
Source: Reuters - 🏆 2. / 97 Read more »

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market valueBiogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex... I'll remember this. Why don’t they learn how to use CBDa? I take issue with the quote attributed to Guggenheim analyst, Yaris Suneja. You would not consider investment in Alzheimer ‘s research a “waste” if a loved one were so afflicted. This is a devastating disease. It takes a brave company to find an answer.
Source: Reuters - 🏆 2. / 97 Read more »

Here's what could bring an end to the market's IPO high, according to one expertWall Street's reaction to money-losing companies like Lyft and Uber going public is a key factor in whether their valuations can hold up, says Renaissance Capital's Kathleen Smith.
Source: CNBC - 🏆 12. / 72 Read more »